Live News EQUITY FLASH L impact Oct 30, 2026, 01:16 PM UTC Guggenheim Maintains Buy Rating on Genmab, Raises Target to $80 Guggenheim maintained its Buy rating on Genmab and raised its price target to $80 from $58. GMAB SquawkNews Desk